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Introduction
MicroRNAs (miRNAs) have been linked to cardiac remodeling, with miR-21 being implicated in cardiac 
fibrosis (1). Using different models of  tissue injury, several, but not all (2), studies reported a reduction of  
cardiac fibrosis with systemic miR-21 inhibition (3–5). miR-21 is ubiquitously expressed in mammalian 
cell types. Besides myocardial fibrosis (3–6), it has been linked to fibrotic kidney (7, 8) and lung disease (9), 
in-stent restenosis and vein graft failure (10–12), and aortic aneurysmal disease (13). As a mechanistic expla-
nation, studies of  miR-21 have suggested an effect on cardiac fibroblast (CF) survival and proliferation that 
may contribute to fibrosis (2–6). miR-21 may also enhance fibrosis through modulating fibroblast senescence 
(14). Surprisingly, miR-21–null mice did not show a difference in cardiac function at baseline or with cardiac 
injury (2). Using a proteomics approach, we have previously reported the first detailed characterization of  
the CF secretome, identifying numerous targets of  miR-29b among extracellular matrix (ECM) proteins 
(15). We pursued a similar approach to investigate the role of  miR-21.
Fibrosis is a major contributor to organ disease for which no specific therapy is available. 
MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 
are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate 
fibrosis using a proteomics approach. Transfection of miR-21 mimic or inhibitor in murine cardiac 
fibroblasts revealed limited effects on extracellular matrix (ECM) protein secretion. Similarly, miR-
21–null mouse hearts showed an unaltered ECM composition. Thus, we searched for additional 
explanations as to how miR-21 might regulate fibrosis. In plasma samples from the community-
based Bruneck Study, we found a marked correlation of miR-21 levels with several platelet-derived 
profibrotic factors, including TGF-β1. Pharmacological miR-21 inhibition with an antagomiR 
reduced the platelet release of TGF-β1 in mice. Mechanistically, Wiskott-Aldrich syndrome protein, 
a negative regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-21. 
miR-21–null mice had lower platelet and leukocyte counts compared with littermate controls but 
higher megakaryocyte numbers in the bone marrow. Thus, to our knowledge this study reports 
a previously unrecognized effect of miR-21 inhibition on platelets. The effect of antagomiR-21 
treatment on platelet TGF-β1 release, in particular, may contribute to the antifibrotic effects of 
miR-21 inhibitors.
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The “master switch” in fibrosis is widely regarded to be TGF-β1. In the heart, TGF-β1 expression is 
induced by an array of  factors, including angiotensin II and mechanical stretch (16). In addition to car-
diomyocytes and CFs, high TGF-β1 levels are also found in blood platelets, where its release is controlled 
by Wiskott-Aldrich syndrome protein (WASp) (17). The platelet releasate is supposed to be a key driver 
of  the inflammatory response in cardiac remodeling (18). It has been suggested that extravasated platelets 
are a major source of  TGF-β1 in the myocardium upon cardiac injury (16). Using megakaryocyte-specific 
TGF-β1–knockout mice, platelet TGF-β1 has indeed been implicated in the development of  cardiac hyper-
trophy and fibrosis in several models of  cardiac remodeling (19–21). We have previously established that 
many of  the abundant circulating miRNAs are of  platelet origin (22). Moreover, there is accumulating evi-
dence that abundant platelet miRNAs, such as miR-223 and miR-126, also affect platelet function (23–25).
In this study, we demonstrate that genetic ablation of  miR-21 reduces the number of  circulating plate-
lets, while pharmacological inhibition attenuates platelet release of  TGF-β1 through miR-21–mediated tar-
geting of  WASp. In contrast, changes in miR-21 levels alter CF proliferation but have no major effect on the 
secretion of  ECM proteins. Furthermore, we show that plasma concentrations of  TGF-β1 are dependent 
on platelets and correlate strongly with miR-21 levels. Thus, in addition to directly acting on fibroblasts, 
miR-21 may contribute to fibrosis indirectly through its effects on platelets.
Results
Mimics and inhibitors of  miR-21 affect murine CF proliferation. Previous studies have reported a role of  miR-21 
in cardiac ECM remodeling, predominantly ascribing the attenuation of  fibrosis upon miR-21 inhibition to 
the nonmyocyte or CF niche of  the cardiac cell population (3, 4, 6, 26). To study the direct effects of  miR-
21 on this cell type using proteomics, CFs were isolated from hearts of  8- to 10-week-old male C57BL/6 
mice as previously described (15). Cultured cells were transfected (Supplemental Figure 1) with a miR-21 
mimic or inhibitor (locked nucleic acid 21 [LNA-21]) and respective controls (n = 4 per group). qPCR 
analysis of  miR-21 levels confirmed a significant and specific effect of  the transfections (Figure 1A and 
Supplemental Figure 2). To assess CF proliferation, cells were plated and monitored using an electrical 
impedance-based assay (xCELLigence). Real-time recording revealed an increase in proliferation within 24 
hours after miR-21 mimic transfection, which was in line with previous findings (3). A concomitant reduc-
tion in proliferation was seen after miR-21 inhibitor transfection (Supplemental Figure 3).
Mimics and inhibitors of  miR-21 have a limited effect on ECM protein secretion. To study the effects of  miR-21 
on the secretion of  ECM proteins, isolated CFs were transfected, followed by stimulation with recombinant 
TGF-β1 or a vehicle control. After 48 hours of  culturing in serum-free conditions, conditioned media were 
collected and processed for secretome analysis (Supplemental Figure 4). As expected, TGF-β1 markedly 
increased secretion of  periostin (fold change [FC] = 4.5 and 10.3, P = 0.008 and 0.008 for miR-21 mimic and 
LNA-21–transfected cells, respectively) and biglycan (FC = 3.5 and 7.0, P = 0.016 and 0.008, respectively). 
No significant differences were observed for decorin and laminin γ1 (Figure 1B and Supplemental Figure 5).
Next, the secretome was analyzed using proteomics. Normalized spectral counts of  ECM proteins 
identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) are provided in Supple-
mental Table 3. Consistent with the immunoblotting results, periostin levels were markedly increased 
by TGF-β1 stimulation (Supplemental Figure 6A). Importantly, secretome levels for the 20 proteins 
with the highest number of  identified spectra, which includes periostin, did not significantly differ after 
miR-21 mimic or inhibitor transfection (Figure 1C). Overall, a marginal effect of  miR-21 on ECM 
secretion was observed (Supplemental Figure 7). After miR-21 mimic transfection, only insulin-like 
growth factor–binding protein 4 (IBP4) and granulin (GRN) showed a significant upregulation in 
unstimulated CFs, whereas higher levels of  GRN, cathepsin L (CATL1), and the α-1 chain of  collagen 
11 (COBA1) were seen in TGF-β1–stimulated cells. Upon miR-21 inhibition, GRN showed a significant 
increase only in TGF-β1–stimulated cells, whereas galectin-3 binding protein (LG3BP) and VCAM-1 
were increased in both unstimulated and TGF-β1–stimulated CFs (Supplemental Figure 8).
To complement the proteomic findings, changes in gene expression were determined. In response to 
TGF-β1, expression of  commonly used markers of  the myofibroblast-like phenotype (Supplemental Figure 
6B), such as α smooth muscle actin (Acta2; FC = 1.6, P < 0.0001), periostin (Postn; FC = 3.2, P = 0.0001), and 
TGF-β1 itself  (Tgfb1; FC = 1.3, P < 0.0001), was increased. Evaluation of  transcripts corresponding to the 20 
proteins with the highest number of  identified spectra (Supplemental Figure 9) and those significantly chang-
ing in the secretome (Supplemental Figure 10) showed a trend toward higher expression of  periostin and the 
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Figure 1. Transfections of cardiac fibroblasts with miR-21 mimic and inhibitor. (A) Cardiac fibroblasts (CFs) were isolated from wild-type mice and 
transfected with miR-21 mimic or LNA-21 (inhibitor), followed by stimulation with TGF-β1 or control treatment. Overexpression and inhibition were 
confirmed by qPCR (n = 8 for each transfection condition; Wilcoxon matched-pairs signed-rank test; lines and error bars represent median [IQR]; 
note that in 3 samples miR-21 was undetectable after transfection with LNA-21). (B) Immunoblotting for several extracellular matrix (ECM) proteins 
showed effects of TGF-β1 treatment but not of miR-21 mimic or inhibitor transfection (n = 4 for each condition). Ponceau S staining was used as load-
ing control. C, control mimic/LNA; 21, miR-21 mimic/LNA-21; Mr, relative mass. TGF-β1 +/– indicates treatment 48 hours prior to conditioned media 
collection. (C) Proteomic analysis of the CF secretome after transfections with miR-21 mimic or inhibitor identified no significant changes in the 20 
most abundant ECM proteins. Four biological replicates were analyzed for each transfection type in the presence or absence of TGF-β1 treatment. No 
statistically significant difference was seen between miR-21 mimic or inhibitor and its respective control for any of the shown proteins, using a FDR < 
0.05, calculated with the Empirical Bayes method.
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transcript encoding LG3BP (Lgals3bp) after miR-21 mimic and inhibitor transfection, respectively. However, 
none of  the changes in expression upon miR-21 overexpression or inhibition reached statistical significance. 
In summary, miR-21 had no major effect on the expression and secretion of  ECM proteins by CFs in vitro.
The cardiac ECM is unaffected in miR-21–null mice. In contrast to the profound effects of  pharmacological 
miR-21 inhibition on the fibrotic phenotype, previous analysis of  miR-21–null mice reported a normal 
cardiac morphology and contractility (2). Since no comprehensive analysis of  their cardiac ECM has been 
performed to date, we evaluated the ECM of  ventricular cardiac tissue from miR-21–null mice and litter-
mate controls (n = 6 per group). qPCR analysis confirmed undetectable levels of  miR-21, whereas no differ-
ences were found for other abundant cardiac miRNAs (Figure 2A, top). Cardiac expression levels of  genes 
encoding various ECM constituents were unaltered in miR-21–null mice (Figure 2A, bottom).
Next, a comprehensive proteomics analysis of  the cardiac ECM was performed using our established 
3-step sequential enrichment protocol (27, 28). FDR-corrected comparisons between both genotypes 
revealed no difference in abundance for any of  the identified proteins (Figure 2B and Supplemental Table 
4) (29). Thus, consistent with our in vitro results, a combined transcriptomic and proteomic analysis of  the 
cardiac ECM revealed no major change upon genetic miR-21 deletion.
miR-21 correlates with levels of  platelet-derived profibrotic factors in the circulation. Given the limited effects on 
ECM secretion by CFs, we explored additional explanations for the observed profibrotic role of  miR-21. 
Previous studies have shown that miR-21 is abundant in hematopoietic cells and the circulation (23, 25, 30). 
We therefore measured 228 proteins in plasma from the community-based Bruneck Study (year 2000 eval-
uation, n = 660), using proximity extension assays, LC-MS/MS, and ELISA. These protein measurements 
were then correlated to circulating miR-21 levels, as determined by qPCR (Figure 3A). A significant correla-
tion was seen between miR-21 and the latency-associated peptide of  TGF-β1 (LAP-TGF-β1; r = 0.65, P < 
0.0001; Figure 3B) as well as several other profibrotic factors, such as PDGF subunit β (PDGFβ; r = 0.73, P 
< 0.0001), suggesting a common origin. Furthermore, miR-21 levels were significantly correlated with those 
of  markers of  platelet activity, such as proplatelet basic protein (PPBP) and platelet factor 4 (PF4), as also 
indicated by gene ontology (GO) analysis for the terms “platelet activation” and “platelet degranulation.” 
These findings are in line with our previous report indicating that circulating miR-21 levels are dependent on 
platelets (23). The correlation between circulating miR-21 and mature TGF-β1 was confirmed by qPCR and 
ELISA analysis, respectively, in platelet-poor plasma (PPP) collected during the 2015 follow-up (n = 332) of  
the Bruneck Study (Figure 3C). Our previous studies have also identified miR-21 as a major platelet miRNA 
(23, 31). To confirm enrichment of  this miRNA in megakaryocytes, argonaute 2 (Ago2) immunoprecipita-
tion was performed in a human megakaryoblastic leukemia cell line (MEG-01). Here, enrichment of  miR-21 
in the Ago2 complex was found, along with 2 previously identified platelet-enriched miRNAs (Figure 3D) 
(25). This suggests a functional role for miR-21 in megakaryocytes and platelets. Altogether, analyses in a 
community-based cohort study and in MEG-01 cells imply a role of  miR-21 in platelets.
TGF-β1 is enriched in megakaryocytes, and plasma levels are dependent on platelets. Colocalization of  TGF-β1 
with PF4 was demonstrated by immunofluorescence staining of  the murine bone marrow (Figure 4A). 
Further magnification of  TGF-β1/PF4–positive cells showed large and lobulated nuclei characteristic of  
megakaryocyte morphology (Figure 4B). TGF-β1 staining beyond the areas of  colocalization with PF4 
was negligible, demonstrating that megakaryocytes are the major source for TGF-β1 in the bone marrow.
To study the dependency of  plasma TGF-β1 levels on platelets, we used an antibody-mediated thrombo-
cytopenia model in wild-type mice (Figure 4C) (32). Successful platelet depletion was confirmed by a signifi-
cant reduction of  platelet-specific gene transcripts (Figure 4D) in whole blood as well as by reduced levels of  
PF4 in PPP (Figure 4E). Ptprc, an abundant transcript in leukocytes encoding the cluster of  differentiation 45 
(CD45), was not affected. Importantly, levels of  TGF-β1 in PPP were significantly decreased (median [inter-
quartile range], 1.9 [1.6–2.1] and 0.78 [0.73–0.84] ng/ml after control or depletion, respectively; P = 0.0025; 
Figure 4F). These findings confirm platelets as the major source of  TGF-β1 in the circulation.
miR-21 affects the release of  TGF-β1 from platelets. Next, we assessed the effect of  miR-21 inhibition on 
platelets using antagomiR-21 treatment in mice (Figure 5A). First, platelet counts were determined by 
flow cytometry using allophycocyanin-CD41 staining (Supplemental Figure 11). No significant difference 
in platelet numbers was found between mice treated with antagomiR-21 or control (Figure 5B). miRNAs 
have previously been shown to alter platelet function (22, 24, 25). To determine whether miR-21 inhibi-
tion altered platelet activation, we measured the aggregation response to various agonists using a similar 
approach as that previously described for miR-126 (25). Unlike miR-126, pharmacological inhibition of  
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miR-21 did not affect the platelet aggregation response to arachidonic acid, protease-activated receptor 4 
(PAR4) amide, or collagen (Figure 5C). In light of  the correlation between miR-21 and TGF-β1 levels in 
human plasma, we evaluated whether plasma levels and platelet release of  TGF-β1 were affected by antag-
omiR-21 (Figure 5D). Interestingly, platelet TGF-β1 release was significantly reduced in response to PAR4 
amide (P = 0.003) and collagen (P = 0.011). The release of  PF4, a marker of  platelet activation, was less 
affected. No differences were seen for levels of  either protein in PPP.
WASp is a direct target of  miR-21. Several platelet-derived factors, including TGF-β1, have previously 
been implicated in cardiac remodeling (19, 33). We therefore determined the effects of  pharmacological 
miR-21 inhibition on the platelet protein releasate in mice. Platelets were isolated from mice treated with 
antagomiR-21 or control, aggregation was induced with thrombin, and the platelet releasate was used 
for proteomic analysis (Figure 6A). In agreement with the findings presented in Figure 5D, TGF-β1 was 
Figure 2. The cardiac ECM of miR-21–null mice. (A) Hearts from miR-21–null mice and littermate wild-type controls were used for RNA isolation. Expres-
sion levels of miRNAs (top) and selected ECM genes based on the CF transfection experiments (bottom) were determined by qPCR. Expression levels of 
U6 and Actb were used as reference transcripts, respectively. (B) The same hearts were used for proteomics by combining our sequential ECM extraction 
procedure with analysis by mass spectrometry. Using normalized precursor intensities, no significant differences were observed between hearts from miR-
21–null mice and littermate controls. An FDR-based approach was used for all 3 analyses using a q < 0.05 for statistical significance. For all 3 analyses, n = 
6 miR-21-null mice vs. n = 6 control mice.
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among the differentially regulated proteins after miR-21 inhibition (log2 FC = –2.86, P = 0.047). Other 
differentially regulated proteins were von Willebrand factor (VWF; log2 FC = –2.67, P = 0.040) and 
fibronectin (FINC; log2 FC = –2.18, P = 0.030). GO annotation identified all 3 proteins with presence in 
the α-granule lumen. Several other proteins with this GO term showed a similar trend of  reduced release 
after antagomiR-21 treatment (Supplemental Table 5).
Platelet TGF-β1 release has previously been shown to be curtailed by WASp (17), an actin assembly pro-
tein selectively expressed in cells of hematopoietic origin (34). To evaluate levels of TGF-β1 and WASp by 
immunoblotting, platelets were isolated and lysed after antagomiR-21 or control treatment. While platelet lev-
els of TGF-β1 (FC = 0.98, P = 0.909) and PF4 (FC = 1.05, P = 0.473) were unaltered upon pharmacological 
miR-21 inhibition, levels of WASp (FC = 1.90, P = 0.047) were significantly increased (Figure 6B and Supple-
mental Figure 12). Analysis of WASp phosphorylation at tyrosine 293 (Y293; p-WASp), which constitutes the 
active form of WASp that restricts platelet TGF-β1 release (17), showed a similar trend (FC = 1.49, P = 0.056). 
Phosphorylation did not differ after normalization for total WASp levels (Figure 6B and Supplemental Figure 
12C). The effect on total WASp levels was confirmed by qPCR in the bone marrow of antagomiR-21–treated 
mice, showing increased Was gene expression levels (FC = 1.08; P < 0.001) (Figure 6C). Target prediction 
Figure 3. Plasma levels of miR-21 and TGF-β1. (A) Plasma miR-21 levels were measured using qPCR in samples from the year 2000 follow-up of the 
community-based Bruneck Study (n = 660). Pearson coefficients for the correlation of miR-21 with circulating proteins associated with cardiovascular 
disease and inflammation were calculated based on measurements by a combination of proximity extension assays, mass spectrometry, and ELISA. Each 
point indicates an individual protein, with its corresponding correlation coefficient on the y axis. PF4, platelet factor 4; PPBP, proplatelet basic protein; 
LAP-TGF-β1, latency-associated peptide of TGF-β1. Black points indicate FDR-adjusted significance < 0.05, with inverted triangles indicating significantly 
correlating proteins that were annotated with the “platelet degranulation” and “platelet activation” gene ontology (GO) terms. (B) The correlation of miR-
21 and LAP-TGF-β1 in plasma of the Bruneck study, year 2000 follow-up. Solid and dashed lines indicate linear regression and 95% confidence interval, 
respectively. NPX, normalized protein expression. q, FDR-corrected P value for Pearson correlation. (C) The correlation of miR-21 and mature TGF-β1, as 
measured by ELISA, using platelet-poor plasma (PPP) from the 2015 evaluation of the Bruneck Study (n = 332). r, Pearson correlation coefficient; P value 
for Pearson correlation. (D) Argonaute 2 (Ago2) immunoprecipitation was performed in lysates from a human megakaryoblastic leukemia cell line (MEG-
01) to isolate coprecipitated RNA. Analysis by qPCR showed enrichment for miR-21, along with miR-126 and -223 (25), suggesting a functional relevance for 
these miRNAs in megakaryocytes. U6 and RNU48 were used as control RNAs. n = 2 for each measurement.
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algorithms have a high false-positive rate (35), with a combination of commonly used algorithms yielding over 
14,000 putative genes for canonical miR-21 targeting (36). A luciferase reporter assay was therefore used to 
evaluate targeting of Was by miR-21. This indeed suggested direct targeting (FC = 0.71; P = 0.003) (Figure 6D). 
To assess whether miR-21 inhibition can affect the expression of WAS in human megakaryocytes, forward-pro-
grammed human pluripotent stem cell–derived (hPSC-derived) megakaryocytes (FoP-MKs) were used (37). 
Two independent lines with >95% megakaryocyte purity (Supplemental Figure 13A) were transfected with a 
Figure 4. TGF-β1 in the bone marrow and circulation. (A) Transverse femoral sections from wild-type mice were used for immunohistochemical analysis 
of the bone marrow (n = 7; representative images shown). Sections were stained for TGF-β1 (red) and PF4 (green). DAPI was used as a nuclear counterstain 
(blue). Scale bar: 200 μm. (B) Images (original magnification, ×60) identifying the cellular and lobulated nuclear morphology characteristic of megakary-
ocytes. Scale bar: 200 μm and 20 μm for ×20 and ×60, respectively.(C) Wild-type mice were treated with a monoclonal antibody directed against GPIbα 
(anti-CD42b; 4 mg/kg intraperitoneally) to deplete platelets. Whole blood and platelet-poor plasma (PPP) were collected 48 hours after injection. (D) 
Expression levels of several platelet genes, as well as Tgfb1, were significantly lower in whole blood after platelet depletion. Expression of Ptprc, widely 
expressed in leukocytes, was not altered. Gapdh was used as reference gene transcript. Lines and error bars represent median (IQR). Statistical analysis 
was performed with Mann-Whitney test; n = 5 (control) versus 7 (anti-CD42b). (E and F) Effect of platelet depletion in mice on PPP levels of TGF-β1 and 
PF4 (Mann-Whitney test, n = 5 for control, n = 7 for anti-CD42b antibody-treated mice). Lines and error bars represent median (IQR).
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nontargeting control or a miR-21 inhibitor, resulting in a significant decrease of miR-21 levels (Figure 6E). In 
line with our findings in murine bone marrow and platelets, as well as the luciferase assay for the murine Was 3′ 
UTR, inhibition of miR-21 resulted in a concomitant increase of WAS expression levels (Figure 6F). No signif-
icant effect was seen on megakaryocyte purity or maturity (Supplemental Figure 13, B–D). Thus, our findings 
indicate that pharmacological miR-21 inhibition leads to derepression of WASp, which has previously been 
shown to affect the release of TGF-β1 from platelets (17).
miR-21–null mice have a reduced number of  circulating platelets. Previous studies into miR-21 and cardiac fibro-
sis have highlighted a discrepancy between pharmacological and genetic inhibition of this miRNA (2, 3). miR-
21–null mice were reported to develop fibrosis in response to myocardial infarction or pressure overload that is 
equivalent to that of wild-type mice. ELISA measurements for TGF-β1 and PF4 in PPP showed no significant 
difference between wild-type and miR-21–null mice. Similarly, platelet levels of WASp and TGF-β1 were also 
Figure 5. Pharmacological inhibition of miR-21 decreases platelet TGF-β1 release. (A) Platelet counts and their aggregation response were assessed in 
whole blood and platelet-rich plasma (PRP), respectively, isolated from mice treated with antagomiR-21 or control antagomiR. ELISAs were subsequently 
performed in the supernatant of aggregated platelets. (B) Platelet counts were assessed by flow cytometry using a CD41-allophycocyanin antibody on 
gated platelets. Statistical analysis was performed with Mann-Whitney test; n = 5 antagomiR-21–treated mice vs. n = 5 control antagomiR-treated mice. 
Lines and error bars represent median (IQR).(C) Platelet aggregation in response to arachidonic acid (AA), protease activated receptor 4 (PAR4) amide, or 
collagen did not show a significant difference after antagomiR-21 treatment (2-way ANOVA with post hoc Šidák’s test; n = 5 for each treatment type). (D) 
TGF-β1 release from platelets in response to collagen and PAR4 amide was reduced after treatment with antagomiR-21. PF4 was less affected. TGF-β1 
levels in platelet-poor plasma (PPP) were unchanged. Statistical analysis was performed with 2-way ANOVA for agonists and Mann-Whitney test for PPP; 
n = 5 antagomiR-21–treated mice vs. n = 5 control antagomiR-treated mice for each condition; *P < 0.05; ***P < 0.001.
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unaffected (Supplemental Figure 14). To assess other potential changes in platelets from miR-21–null mice, we 
performed a whole-blood platelet count using a Hemavet hematology analyzer. In contrast to short-term phar-
macological inhibition of miR-21, blood from miR-21–null mice showed significantly lower platelet counts 
compared with wild-type littermates (Figure 7A). Lymphocyte and monocyte numbers were also reduced but 
still fell within the normal reference range. To determine the megakaryocyte response to the lower platelet 
count, immunohistological staining of the bone marrow was performed in decalcified femoral sections (Figure 
7B). A significant increase in megakaryocyte numbers was seen in miR-21–null bone marrow, with a median 
(interquartile range) count per mm2 of 84.7 (78.0–90.0) and 106.3 (99.5–121.2) for wild-type and miR-21–null 
mice, respectively (P = 0.003 for Mann-Whitney test) (Figure 7C). We next studied gene expression levels in 
the bone marrow of these mice (Figure 7D). No significant differences were seen for expression of Tgfb1, Ptprc 
(CD45), or Was. However, transcript levels of several megakaryocyte-specific genes were significantly higher 
(FC = 1.70 [P = 0.005] for Itga2b, 1.72 [P = 0.026] for Pf4, 1.90 [P = 0.030] for Ppbp). Furthermore, there was a 
trend toward higher expression levels for Tgfbr2 (FC = 1.32, P = 0.055), a previously described direct target of  
miR-21 (38). Altogether, platelet and megakaryocyte numbers are altered in miR-21–null mice.
Figure 6. Pharmacological inhibition of miR-21 affects platelet TGF-β1 release through targeting Wiskott-Aldrich syndrome protein. (A) The platelet 
releasate was obtained by thrombin-mediated activation of washed platelets collected from antagomiR-21– or control-treated mice. Proteomics 
analysis uncovered an attenuated release of TGF-β1 and 2 other α-granule proteins, von Willebrand factor (VWF) and fibronectin (FINC), from platelets 
isolated after antagomiR-21 treatment. Statistical analysis was performed using Welch’s t test (n = 3 vs. 3 biological replicates; pooled from n = 12 
antagomiR-21–treated mice and n = 12 control antagomiR–treated mice). (B) Platelets were isolated from mice after miR-21 inhibition. Immunoblots 
showed higher levels of Wiskott-Aldrich syndrome protein (WASp), while TGF-β1 content was unchanged (n = 4 antagomiR-21–treated mice vs. 4 con-
trol antagomiR–treated mice; statistical comparisons of densitometry using Welch’s t test). Similarly, WASp phosphorylation at tyrosine 293 (p-WASp; 
Y293) was unaffected.(C) Gene expression of Was in murine bone marrow after antagomiR-21 treatment was assessed by qPCR (n = 9 antagomiR-21–
treated mice vs. 9 antagomiR control–treated mice; Welch’s t test). Actb was used as a normalization control. (D) Transfection of HEK293T cells with 
miR-21 mimic significantly suppressed luciferase reporter activity using vectors harboring the 3′ untranslated region of Was (3 independent experi-
ments in triplicates [control] or quadruplicates [miR-21 mimic]; paired t test used for statistical comparison). (E and F) Megakaryocytes were produced 
by forward programming (FoP-MK) of human pluripotent stem cells (hPSCs). Upon transfection with a miR-21 inhibitor (LNA-21), miR-21 levels were 
markedly reduced. The inhibition of miR-21 was accompanied by increased gene expression levels of WAS (n = 6 LNA-control transfections vs. 6 LNA-21 
transfections; Welch’s t test). *P < 0.05, **P < 0.01, ***P < 0.001. Mr, relative mass.
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Discussion
In this study, we identify a potential novel mechanism for the antifibrotic effects of  miR-21–targeted therapy: 
notably, miR-21 minimally affects ECM protein secretion by CFs in vitro and in miR-21–null mice. Instead, 
miR-21 levels correlate with several platelet-derived profibrotic factors in the circulation, and its genetic 
ablation decreases platelet counts. Short-term pharmacological miR-21 inhibition attenuates the release of  
TGF-β1 from platelets. This suggests that pharmacological inhibition of  miR-21 acts systemically in addi-
tion to its effects on CF proliferation. On the other hand, genetic deletion of  miR-21 reduces platelet num-
bers and stimulates megakaryocyte proliferation. These findings may have implications for miR-21–based 
therapeutics, in particular with regard to local versus systemic delivery.
Direct effects of  miR-21 in the heart. There is strong evidence for the contribution of miR-21 in fibrosis. Sys-
temic inhibition could prevent and even reverse cardiac fibrosis in a pressure-overload model (3), which was 
confirmed in most (4, 5), but not all (2), studies. Fibroblasts are the primary contributors to fibrosis (39, 40), 
with the TGF-β pathway playing a central role in fibroblast activation. Despite enhancing CF proliferation, 
miR-21 had no major effect on cardiac ECM protein secretion. These findings are in stark contrast with previ-
ous studies that revealed major changes in ECM protein secretion using a similar approach for miR-29b (15) 
and hypoxia (41). Experiments in CFs were performed based on equal cell numbers prior to transfection and 
Figure 7. miR-21–null mice display 
lower platelet and leukocyte num-
bers but higher numbers of mega-
karyocytes. (A) Using Hemavet blood 
cell counting, significantly lower num-
bers of platelets, lymphocytes, and 
monocytes were found in miR-21–null 
mice (n = 6) compared with those in 
wild-type littermates (n = 10) (Welch’s 
t test). (B) Immunohistochemical 
analysis was performed for TGF-β1 
(red), PF4 (green), and a nuclear coun-
terstain (DAPI, blue), using femoral 
bone marrow sections of miR-21–null 
mice (n = 10). Representative images 
are shown. (C) Examination of bone 
marrow sections from miR-21–null 
mice revealed increased megakaryo-
cyte numbers, as identified based on 
morphology and PF4 positivity. Statis-
tical comparison was performed using 
the Mann-Whitney test; n = 6 vs. 10 
for littermate control and miR-21–null 
mice, respectively. Lines and error 
bars represent median (IQR). (D) qPCR 
analysis revealed increased expres-
sion levels of megakaryocyte-specific 
genes Itga2b, Pf4, and Ppbp in bone 
marrow cells isolated from miR-21–
null and littermate control mice. Tran-
script levels of Tgfb1, Was, and Ptprc 
(CD45) were not affected. Statistical 
comparisons using Welch’s t test; n = 
6 vs. 6. *P < 0.05, **P < 0.01.
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TGF-β1 treatment. Hence, it can be stated that, despite enhancing proliferation, this antiproliferative effect 
of miR-21 inhibition was insufficient to cause detectable changes in total ECM protein secretion. Previous 
discrepancies between studies on miR-21 and cardiac fibrosis have been ascribed to differences between phar-
macological and genetic miR-21 inhibition (42). In line with our in vitro findings and with functional cardiac 
analysis by others (2), the composition of the cardiac ECM did not significantly differ in miR-21–null mice. 
A recent study by Ramanujam et al. used viral vectors with different tropism to distinguish effects of miR-21 
inhibition in different cardiac cell types (26). While cardiomyocyte inhibition of miR-21 aggravated fibrosis, 
nonmyocyte targeting attenuated remodeling in a mouse model of cardiac overload. Importantly, effects of  
miR-21 on cardiac fibrosis are observed only in the presence of tissue injury (3–6).
miR-21 as a modulator of  the bone marrow. miR-21 is ubiquitously expressed and has been implicated 
in fibrosis in different organs (7–9). Furthermore, miR-21 is highly abundant in circulating cells, such as 
monocytes and platelets (43). Recent studies on atherosclerosis identified an immunomodulatory role of  
miR-21 in mononuclear cells (12, 30, 44). Leukocytes and platelets are major contributors to the tissue injury 
response (45). Thus, the widely reported induction of  miR-21 upon injury may be secondary to an immune 
cell infiltration or platelet deposition rather than induction of  miR-21 expression in resident cells (46). In 
addition, expression and processing of  the miR-21 precursor is enhanced by TGF-β signaling (47). A platelet 
contribution may explain why miR-21 inhibition has no effect on fibrosis in the absence of  tissue injury. Tis-
sue injury induces platelet activation. In addition to local fibroblast activation, platelet-derived proteins (33), 
including TGF-β1 (19), contribute to the onset and progression of  fibrosis. Platelet inhibition or depletion 
attenuates cardiac remodeling after myocardial infarction (48, 49) or in response to pressure overload (18, 
33). We have previously demonstrated that miR-21 is abundant in platelets and miR-21 plasma levels are 
decreased by antiplatelet therapy (23). Ago2 immunoprecipitation showed marked enrichment of  miR-21 
in a human megakaryoblastic leukemia cell line. Bone marrow cells are more readily affected by antagomiR 
treatment compared with cardiac tissue (50). This is in contrast with the absence of  miR-21 across tissues 
upon genetic ablation in mice. In miR-21–null mice, we found no major effect on cardiac ECM proteins, but 
we observed significantly lower platelet and leukocyte counts, accompanied by a marked increase in mega-
karyocyte numbers. Altogether, these findings imply that miR-21 inhibition alters the bone marrow.
Pharmacological miR-21 inhibition affects the platelet releasate. Platelets constitute a major source of  circu-
lating TGF-β1 (19). This is reflected in the strong correlation between plasma levels of  miR-21 and TGF-β1 
in the Bruneck cohort and by the reduction in TGF-β1 plasma levels upon platelet depletion in mice. In the 
bone marrow of  mice, we observed a striking colocalization of  TGF-β1 with megakaryocytes. Pharmaco-
logical inhibition of  miR-21 did not alter the platelet count or their aggregation response but significantly 
decreased the release of  several α-granule proteins. Our observation of  miR-21 inhibition affecting platelet 
TGF-β1 release suggests a feed-forward mechanism, where TGF-β1 induces miR-21 expression in mega-
karyocytes, which subsequently enhances platelet TGF-β1 release through inhibiting WASp. WASp has 
been described as a regulator of  actin polymerization in neutrophils, macrophages, and lymphocytes (51), 
being expressed solely in hematopoietic cells (34). While WASp is present in platelets, it is not required 
for platelet spreading, despite the importance of  cytoskeletal F-actin polymerization in this process (52). 
This indicates redundancy in the mechanisms that regulate actin polymerization in platelets. Consequent-
ly, miR-21–mediated titration of  WASp levels may be a refined way of  interfering with TGF-β signaling. 
Previous approaches of  TGF-β1–targeting therapy have thus far failed due to major side effects (53). Alter-
ing the platelet release of  profibrotic factors may provide a more targeted approach, as platelet activation 
occurs at sites of  tissue injury. In summary, our findings provide evidence that the reported antifibrotic 
effects upon miR-21 inhibition may, at least in part, occur through decreasing platelet release of  TGF-β1.
Study limitations. The culture of  CFs for secretome analysis was performed in serum-free medium. This 
may have suppressed some of  the effects of  miR-21 in these cells. In addition, ECM proteins were assessed 
only in miR-21–null mice without cardiac injury to promote fibrosis. Correlations between miR-21 and 
markers of  platelet activation or profibrotic factors do not rule out potential confounding by contaminat-
ing leukocyte subtypes. For TGF-β1, however, the immunohistochemistry results from the bone marrow 
indicate a high degree of  specificity for megakaryocytes. Our findings suggest that antagomiR-21 treat-
ment may reduce TGF-β1 release through derepressing WASp. While direct targeting was indicated by a 
luciferase reporter assay and by miR-21 inhibition in hPSC-derived megakaryocytes, in vivo evidence for 
this interaction is correlative. In addition, as suggested by the proteomic analysis of  the platelet releasate, 
antagomiR-21 treatment may affect release of  other α-granule proteins as well. Further studies are needed 
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to determine whether miR-21 has effects on the release of  other constituents of  platelets and on leukocytes, 
given that WASp is predominantly expressed in hematopoietic cells and Wiskott-Aldrich syndrome is char-
acterized by immune deficiency as well as thrombocytopenia (34).
Conclusions. This study is a timely contribution, given that miR-21–based therapies are progressing to 
clinical trials for Alport syndrome (7). The current assumption that miR-21 inhibition attenuates fibrosis pre-
dominantly through direct effects on fibroblasts is challenged by the marginal changes in ECM protein com-
position and secretion. Our findings after pharmacological and genetic miR-21 inhibition in mice indicate that 
other cell types, in particular bone marrow–derived cells, may also contribute. While local delivery of  miRNA 
therapeutics may decrease the likelihood for off-target effects (10), it could also limit therapeutic efficacy if  
the benefit is not solely mediated by local cells. A broad appraisal of  the multifaceted systemic response of  
targeting ubiquitously expressed miRNAs will aid the success of  miRNA-based therapeutics in clinical trials.
Methods
Detailed methods are provided in the Supplemental Methods.
RNA isolation, reverse transcription, and PCRs. RNA isolation, reverse transcription (RT), and preamplifi-
cation as well as individual quantitative real-time PCR (qPCR) for miRNA and gene expression were per-
formed as described previously (25). A comprehensive list of  assays is provided in Supplemental Table 1.
CF isolation and transfection for secretome analysis. Primary mouse CFs were isolated from the hearts 
of  male (8- to 10-week-old; n = 8) C57BL/6 mice (Charles River) by collagenase II–based digestion as 
described previously (15). Cells from different animals were maintained as separate biological replicates. 
Cells at passage 3 were used in all experiments. Transfections of  miR-21 mimic (Dharmacon) or miR-21 
inhibitor (LNA-21; Exiqon A/S) were each carried out, with corresponding controls in parallel using 4 
separate biological replicates. Lipofectamine RNAiMAX (Life Technologies) was used in reduced serum 
medium (Opti-MEM, Life Technologies) at a final concentration of  50 nmol/l for transfection of  all 4 
sequences. After 24 hours, CFs were stimulated with 10 ng/ml recombinant TGF-β1 (Peprotech) in serum-
free medium. After 48 hours, conditioned medium and cells were harvested for analysis. Samples were 
processed for qPCR analysis, immunoblotting, or proteomic analysis as described previously (15) and in the 
Supplemental Methods. See complete unedited blots in the supplemental material.
Proliferation assay in transfected CFs. A proliferation assay was performed using the xCELLigence RTCA 
DP Instrument (ACEA Biosciences). CFs were isolated and transfected using the same methods and con-
centrations as above. After 24 hours, cells (5 × 103 cells/well; 4 biological replicates per condition, in dupli-
cate) were seeded in an E-Plate VIEW 16 (ACEA Biosciences) in complete DMEM medium. Following 
plating, cells were allowed to attach while at room temperature for 30 minutes before placing the plate in 
the incubator at 37°C. Two wells per plate were loaded with media only to assess background levels. Cell 
index values were recorded by 150 sweeps per interval every 30 minutes using proprietary software, with 
the baseline recording reset at 4 hours. Data were analyzed using the difference (Δ) in cell index according 
to the manufacturer’s instructions with the baseline recording reset at 4 hours.
ECM extraction and analysis. ECM protein enrichment was performed on hearts from female miR-21–null 
mice or littermate controls, aged 14–16 weeks, using our previously published 3-step extraction method (28, 
54). Generation of  the miR-21–null mice has previously been described (2). Proteins in the sodium chloride 
and guanidine hydrochloride extracts were enzymatically deglycosylated, followed by denaturation, reduc-
tion, alkylation, and tryptic digestion. Peptides were purified using a C18 spin plate (Harvard Apparatus) 
and analyzed by LC-MS/MS. Identified proteins were annotated using the Matrisome database (29).
Bruneck cohort. The Bruneck Study is a community-based, prospective survey of  the epidemiology and 
pathogenesis of  atherosclerosis and cardiovascular disease (25, 55). At the 1990 baseline evaluation, the 
study population comprised an age- and sex-stratified random sample of  all inhabitants of  Bruneck (125 
men and 125 women from each of  the fifth through eighth decades of  age, all White). In the present study, 
citrate plasma samples from the 2000 (n = 660) and 2015 (n = 332) follow-up were analyzed. These samples 
were drawn after an overnight fast and 12 hours of  abstinence from smoking. During the 2000 follow-up, 
citrate plasma was prepared by single centrifugation and aliquots were immediately stored at –80°C. For the 
2015 follow-up, platelet-rich plasma (PRP) was first isolated by centrifugation at 175 g for 15 minutes with 
slow brake. An aliquot of  PRP was then supplemented with prostacyclin (PGI2, epoprostenol, 2 μg/ml; Toc-
ris Bioscience) and centrifuged at 1,000 g for 10 minutes to obtain PPP. Samples were immediately stored at 
–80°C. Levels of  miR-21 and a panel of  228 proteins were measured by RT-qPCR (25) and a combination 
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of  Olink Proseek Proximity Extension Assays (Proseek Multiplex CVD I and Inflammation panels, Olink) 
(55, 56) and mass spectrometry–based assays (PlasmaDive, Biognosys AG) (57), respectively, as described 
previously (25). In addition, TGF-β1 (DY240, R&D Systems), PF4 (DY795, R&D Systems), and PPBP 
(DY393, R&D Systems) levels were measured using DuoSet ELISA Development kits and DuoSet Ancil-
lary Reagent Kits 1 and 2 (R&D Systems) according to the manufacturer’s instructions. Absorbance at 450 
nm was measured on a plate reader (Tecan Infinite 200 Pro) using 570 nm as a reference wavelength. Results 
were calculated using a 4-parameter logistic fit.
Platelet immunodepletion in mice. Male C57BL/6J mice (Charles River) were treated with a rat anti-mouse 
GPIbα antibody (4 mg/kg, Emfret Analytics) or sterile PBS via intraperitoneal injection. Blood was col-
lected after 48 hours into acid-citrate-dextrose buffer by cardiac puncture, followed by preparation of  PRP 
and PPP using serial centrifugation at 100 g and 1,000 g for 10 minutes at room temperature, respectively. 
Samples were divided into aliquots, blinded, randomized, and immediately stored at –80°C. RNA isolated 
from whole blood was used for qPCR analysis. TGF-β1 (DY1679) and PF4 (DY595) levels were measured in 
PPP using DuoSet ELISA Development kits (R&D Systems) according to the manufacturer’s instructions.
Ago2 immunoprecipitation. Immunoprecipitation of  ribonucleoprotein was carried out in MEG-01 cells 
(ATCC, CRL-2021), as previously described (25, 58). Briefly, 50–100 million cells were lysed in 500 μl ice-
cold polysome lysis buffer (5 mM MgCl2, 100 mM KCl, 10 mM HEPES, pH 7.0, 0.5% Nonidet P-40), with 
freshly added 1 mM DTT, 100 U/ml RNase inhibitor (Life Technologies) and 1× protease inhibitor (cOm-
plete Mini, ethylenediaminetetraacetic acid–free [EDTA-free], Roche) for 15 minutes. Centrifugation was 
performed at 14,000 g at 4 °C for 10 minutes. The supernatant was mixed with 500 μl ice-cold NT2 buffer 
(50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% Nonidet P-40) containing freshly added 200 U/
ml RNase inhibitor, 0.5% vanadyl ribonucleoside, 1 mM DTT, 15 mM EDTA, and 50 μl mouse anti-hu-
man Ago2-coated (Abcam) sepharose G beads (Life Technologies). Incubation was carried out overnight 
at 4°C on a rocking platform. The following day, beads were washed 5 times with ice-cold NT2 buffer and 
used for RNA isolation.
Murine platelet and bone marrow analysis. For pharmacological miR-21 inhibition, male C57BL/6J mice, 
aged 10–12 weeks (Charles River), were injected intraperitoneally with cholesterol-conjugated antagomiR 
constructs (Fidelity Systems) targeting miR-21 or using a nontargeting sequence, as previously described (25). 
Sequences were designed to target miR-21 (5′-U*C*AACAUCAGUCUGAUAAG*C*U*A*-Chol*T-3′) 
or to serve as nontargeting control (5′-A*A*GGCAAGCUGACCCUGAA*G*U*U*-Chol*T-3′), with 
the asterisks denoting phosphorothioate backbone modification and “Chol” indicating cholesterol con-
jugation. Constructs were reconstituted in sterile PBS, and intraperitoneal injections of  500 μl were per-
formed on day 0, 1, and 2 in a dose of  25 mg/kg for the platelet releasate isolation and 40 mg/kg for the 
aggregometry experiments and the ELISA measurements in plasma. Treatment with both constructs was 
performed in parallel. On day 7, mice were anesthetized using pentobarbital for blood and tissue collection. 
Upon sample collection, samples were blinded and randomized prior to analysis. Blood and bone marrow 
samples were obtained from equal numbers of  male and female miR-21–null mice (Mir21atm1Yoli/J, Jax 
016856; The Jackson Laboratory) and littermate controls, aged 8–12 weeks. Mice were kept under constant 
temperature and humidity in a 12-hour-controlled dark/light cycle.
A Hemavet (Drew Scientific) blood cell counter was used for analysis of  miR-21–null blood samples. 
Platelet counting after antagomiR-21 treatment was performed on diluted whole blood incubated with an 
allophycocyanin-labeled anti-mouse CD41 antibody (BioLegend), using an Accuri C6 flow cytometer (BD 
Biosciences). Light transmission aggregometry was performed with PRP as described previously (25). Plate-
lets were isolated by blood collection into acid-citrate-dextrose buffer, followed by 2-step centrifugation and 
washing in modified Tyrode-HEPES buffer supplemented with prostaglandin E1. PPP was isolated by 2-step 
centrifugation, obtaining PRP followed by a second spin to obtain PPP. TGF-β1 and PF4 levels were mea-
sured in PPP and light transmission aggregometry supernatants using DuoSet ELISA Development kits 
(R&D Systems) according to the manufacturer’s instructions. Releasate was obtained by thrombin-induced 
platelet aggregation in platelets obtained from blood pooled from 4 mice, followed by gel-based LC-MS/MS 
analysis. Bone marrow cells were isolated from femora and filtered using a 100-μm cell strainer (Corning), 
followed by red blood cell lysis and subsequent RNA isolation for qPCR analysis. For immunohistochemistry, 
femora were fixed in 4% formaldehyde and then decalcified in a 0.38 mol/l EDTA solution at 4°C for 3 weeks. 
Bones were paraffin embedded and sectioned for staining. After primary antibody incubation (TGF-β1 and 
PF4; see Supplemental Table 2) overnight, sections were incubated with fluorescently labeled species-specific 
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secondary antibodies. Staining was visualized using an inverted spinning disc confocal microscope (Nikon 
Ti-Eclipse, teamed with a Yokogawa CSU-X1 Andor Spinning Disc with iXon EM-CCD camera). Imaging 
was performed with a 1.70 NA ×20 or 1.40 NA ×60 magnification objective lens.
Transfection of  miR-21 inhibitor in human megakaryocytes. Human megakaryocytes were obtained by for-
ward programming of  hPSCs as previously described (37). Transfections of  miR-21 inhibitor or a nontarget-
ing control (PowerLNA, Qiagen) were carried out in triplicate in 2 independent megakaryocyte lines. Con-
jugation to TurboFect reagent (Thermo Scientific) was used to enhance the transfection efficiency. A final 
concentration of  25 nmol/l was used for both oligonucleotides. After 48 hours, cells were collected for RNA 
isolation by centrifugation at 120 g and washed once in sterile PBS. Prior to transfection and during collec-
tion, an aliquot of  cells was incubated with anti-CD41a-APC-H7 and anti-CD42a-APC (BD Pharmingen) to 
assess megakaryocyte purity and maturity, respectively, using a Gallios flow cytometer (Beckman Coulter).
Statistics. Gel-based MS data were quantified using normalized spectral counts. Qspec (59) was used to 
detect differential expression in the CF secretome analysis. Qspec utilizes a hierarchical Bayes estimation 
of  a generalized linear mixed-effects model to share information across proteins, which increases the power 
to detect differential expression. The FDR was calculated using an Empirical Bayes method, and FDR < 
5% was considered significant. All other statistical analyses were performed with Microsoft Excel (version 
15.41) and GraphPad Prism (version 7.0d). Distribution of  data was analyzed using the Shapiro-Wilk 
normality test, where P > 0.05 was considered to indicate normal distribution. When at least 1 sample 
group within an experiment showed nonnormal distribution, nonparametric tests were used for the analy-
sis. For unpaired data, 2-tailed Welch’s t test or Mann-Whitney rank tests were performed for parametric 
and nonparametric distribution, respectively. For paired data, paired t tests or Wilcoxon’s matched-pairs 
signed-ranks tests were used, respectively. Where appropriate, a 2-way ANOVA was used, with post hoc 
analysis of  individual effects by Šidák’s test. Time course data of  the CF proliferation assay were analyzed 
using the nonparametric Friedman test with post hoc analysis of  differences between each targeting and 
nontargeting transfection type using Dunn’s multiple comparisons test. Comparison of  gene expression and 
ECM protein abundance between miR-21–null or wild-type mice was performed using an FDR approach 
with the 2-stage step-up method of  Benjamini, Krieger, and Yekutieli, with an FDR for significant discov-
ery set to 5%. Relationships between the concentrations of  plasma proteins and the relative quantities of  
miRNAs were investigated using Pearson correlations with P value adjustment (producing q values) using 
FDR adjustment according to Benjamini, Krieger, and Yekutieli. Data are shown as mean ± SEM unless 
stated otherwise. Where box-and-whisker plots are shown, the line indicates the median, bounds of  boxes 
indicate quartiles, and whiskers indicate the range. P < 0.05 or q < 0.05 was considered significant.
Study approval. The Bruneck study protocol was reviewed and approved by the ethics committees of  
Verona and Bolzano, Italy, and all participants provided written informed consent before entering the study. 
All animal studies were performed under protocols in strict accordance with the UK Animals (Scientific Pro-
cedures) Act 1986 or the Institutional Animal Care Use Committee of  Yale University School of  Medicine.
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